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Identifying molecular markers of endometrial hyperplasia (neoplasia) progression is critical to cancer prevention. To assess RNA
andDNAquantityandqualityfromroutinelycollectedendometrialsamplesandevaluatetheperformanceofRNA-andDNA-based
arrays across endometrial tissue types, we collected fresh frozen (FF) Pipelle, FF curettage, and formalin-fixed paraffin-embedded
(FFPE) hysterectomy specimens (benign indications) from eight women. Additionally, neoplastic and uninvolved tissues from 24
FFPE archival hysterectomy specimens with endometrial hyperplasias and carcinomas were assessed. RNA was extracted from 15
of16FFand51of51FFPEsamples,withyields>1.2𝜇gfor13/15(87%)FFand50/51(98%)FFPEsamples.ExtractedRNAwasofhigh
quality; all samples performed successfully on the Illumina whole-genome cDNA-mediated annealing, selection, extension, and
ligation (WG-DASL) array and performance did not vary by tissue type. While DNA quantity from FFPE samples was excellent,
qualitywasnotsufficientforsuccessfulperformanceontheAffymetrixSNPArray6.0.Inconclusion,FFPipellesamples,whichare
minimally invasive, yielded excellent quantity and quality of RNA for gene expression arrays (similar to FF curettage) and should
be considered for use in genomic studies. FFPE-derived DNA should be evaluated on new rapidly evolving sequencing platforms.
1. Introduction
Though endometrial carcinoma is the most common gyne-
cologic malignant neoplasm [1], diagnostic capabilities and
management of endometrial precancer (intraepithelial neo-
plasia) lag far behind those of cervical carcinoma [2]. A
neoplastic continuum from simple, to complex, to atypical
hyperplasia, to endometrial carcinoma is suggested from
longitudinal epidemiologic studies [3–5]. Identification of
molecularalterationspresentinvariousstagesofendometrial
neoplasia will provide the basis for early detection and thera-
peutics[6].Presentdiagnosticcapabilitiesutilizinghistologic
evaluation for endometrial hyperplasia/neoplasia alone are
limited by poor diagnostic reproducibility [7]a n dr e l a t i v e l y
low prognostic value. Risk of progression to carcinoma
among women with a diagnosis of endometrial hyperplasia
with atypia is not well understood, though exposure to2 Obstetrics and Gynecology International
p r o g e s t i nt h e r a p yh a sb e e nr e p o r t e dt ob ea s s o c i a t e dw i t h
an approximately 60% decreased risk of progression [4, 8].
Futurestudiesthatattempttoelucidatemolecularbiomarkers
of endometrial hyperplasia progression risk will require
the development of two methodologies: the ability to per-
form array studies from extremely small fresh endometrial
samples, as well as high-fidelity large-scale affordable array
interrogation of archived FFPE samples. Potential challenges
exist with both.
The growing field of genomic technologies has made
large array-based studies of somatic mutations possible;
w h o l ee x o m es e q u e n c i n ga n dm u t a t i o nd e t e c t i o nh a v el e dt o
identification of potential driver cancer genes in endometrial
cancer [9, 10]. Tissue archives of longitudinal endometrial
neoplasia (intraepithelial neoplasm) specimens represent a
potentially valuable resource for genomic studies, but they
are typically comprised of formalin-fixed paraffin-embedded
(FFPE) samples [4, 5]. High-quality nucleic acids necessary
for gene expression profiling are most readily obtained from
fresh or fresh frozen samples, as the purity and quantity
of extracted RNA and DNA from archival tissues can be
highly variable [11]. However, the whole-genome cDNA-
mediated annealing, selection, extension, and ligation (WG-
DASL) Assay (Illumina, San Diego, CA, USA) [12]h a s
been implemented using partially degraded RNA extracted
from FFPE tissues for breast carcinoma [13–15]a n do v a r -
ian carcinoma [16], with varying degrees of success. It is
e s s e n t i a lt oe v a l u a t et h eq u a n t i t ya n dq u a l i t yo fR N Aa n d
DNA obtained from endometrial FFPE samples and their
performance on high-throughput arrays to determine the
feasibility of using these readily available tissue archives to
further our understanding of longitudinal progression of
endometrialneoplasmsandimprovediagnosticaccuracyand
thereby, therapeutic choices.
Women diagnosed with endometrial neoplasia present
with abnormal or heavy bleeding patterns and are usually
first evaluated with office endometrial biopsies [17, 18], often
sampledatmultipletimepoints.Samplesareobtainedblindly
using a disposable suction device placed into the uterus,
which results in random sampling that is not oriented to
uterine site. The most common device is a Pipelle. The small
diameter (3mm) and flexible plastic suction curette improve
tolerabilityofthisofficeprocedure.Volumesoftissuesamples
obtained are usually 1-2 cubic centimeters (cc) or less than
1c ci na t r o p h i cs a m p l e s ,a n dc a nb eg r e a t e rt h a n3c ci n
proliferative samples, for example, endometrial hyperpla-
sia/neoplasia. Moving forward, in the clinical scenario of
a woman presenting with abnormal bleeding, we envision
holding a small amount of fresh office endometrial biopsy
specimen for biomarker analysis while retaining the bulk of
the specimen for FFPE clinical diagnostic analysis.
To address whether the quantity and quality of RNA
obtainedfromofficeendometrialsamplesandarchivedFFPE
endometrial tissues were suitable for downstream array
a n a l y s e s ,w ec o m p a r e dt h eq u a l i t ya n dq u a n t i t yo fR N A
isolated from three endometrial specimen types from the
same individual (a) Pipelle suction (blind, random, small
v o l u m e ,s i n g l ep a s so n l y ) ;( b )c u rettage (nonblind, oriented
fundus to cervix from bivalve hysterectomy specimen); and
( c )F F P Es u r g i c a lh y s t e r e c t o m ys p e c i m e n s ,a sw e l la sp a i r e d
endometrial hyperplasias and carcinomas and uninvolved
myometrium from archived FFPE specimens. We also exam-
ined DNA yield and DNA performance on the Affymetrix
SNP 6.0 platform in a subset of samples.
2. Materials and Methods
2.1.StudyParticipantsandBiologicalSamples. Thisstudywas
approved by the University of Washington Human Subjects
Division.
2.2. Fresh Tissue Collection. To assess whether quantity,
quality, and performance of RNA and DNA obtained from
different types of FF and FFPE endometrial samples from
the same person varied by sample type, we enrolled eight
womenundergoingtotalabdominalhysterectomyforbenign
conditions in July and August of 2009. Indications for
hysterectomy (not mutually exclusive) were irregular heavy
bleeding (𝑛=6 ); uterine prolapse (𝑛=1 ), and fibroids
(𝑛=4 ). For each patient, three types of samples were colle-
cted: (1) fresh Pipelle (CooperSurgical Inc.) biopsy; (2)
fresh curettage biopsy; and (3) FFPE hysterectomy surgical
sections. Immediately following removal of the uterus, a
single pass with a Pipelle curette was performed and tissues
were placed into tissue culture media (minimum essential
media (MEM) with 5% fetal calf serum, 5mM HEPES buffer,
and 10% DMSO) on ice for storage at −30
∘C. No RNAlater
s a m p l ew a so b t a i n e da sw eh a dn od a t at og u i d ew h e t h e r
the endometrial sample obtained with one pass would be of
sufficient volume for both diagnostic and research purposes;
our primary focus was on the performance of the MEM-
preserved specimens. The uterus was then bivalved and the
endometrium was sharply curetted in two passes from the
fundus to the junction of the uterus and the cervix. One
curettage sample was placed into MEM, and the second
sample was placed into RNAlater (Qiagen, Valencia, CA,
USA), a medium suitable for long-term storage of tissues
for both RNA and DNA extractions. Both curettage samples
were placed on ice at −30
∘Cu n t i lfr o z e nf o rs t o r a g ea t−70
∘C.
The uterus was then sectioned and processed into FFPE hys-
terectomy samples for histopathology. Each method of tissue
harvesting potentially samples different cell types. Pipelle
biopsies sample the endometrial lining, while the curettage
biopsies are comprised of predominantly endometrial tissue
but may contain myometrial cells. The FFPE hysterectomy
specimens contain both endometrial and myometrial cell
types.
We were able to obtain sufficient tissue for analysis from
7of8FFPipelle(MEM),8of8FFcurettage(MEM),5of8FF
curettage(RNAlater)samples,andall8hysterectomysamples
(FFPE) (Table 1(a)).
2.3. Archival Tissue Collection. To assess quantity and quality
of DNA and RNA from older archived clinical samples
and performance on the WG-DASL and SNP 6.0 platforms,
we selected 24 FFPE hysterectomy specimens: 6 complex
hyperplasias;6atypicalhyperplasias;and12carcinomasfrom
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sampleswerecollectedbetween1999and2009andstoredfor
an average of 4.4 years (range 1 to 11 years) before tissue cores
were collected for RNA and DNA extraction.
All FFPE surgical histopathology slides were reviewed by
a pathologist to identify and mark blocks with representative
and adequate areas of the various tissue types for RNA
and DNA extraction. For the specimens with hyperplasia,
uninvolvedendometriumwasmarkedforsampling7–10mil-
limeters away from the involved hyperplastic endometrium.
For the specimens with carcinoma, uninvolved myometrium
was identified for sampling from separate blocks without
carcinoma. Samples were obtained from the paraffin blocks
b yc o r i n gt h em a r k e da r e a ( s )o ft h ei d e n t i fi e dt i s s u ew i t ha
warm18-gaugeneedle.Approximately15coreswerecollected
p e rs a m p l ea n dt h et o t a lc o r ew e i g h tw a sr e c o r d e d ;u pt o
37mg of paraffin-embedded tissue (range, 11–37mg). Cores
c o l l e c t e df r o me a c ht i s s u et y p ew e r ep l a c e di n t os e p a r a t e
microcentrifuge tubes, deparaffinized, and extracted using
theQiagenBloodandTissueDNeasyspincolumnsaccording
to the manufacturer’s protocol.
Intotal,weobtainedFFPEtissuefor51samples,including
the benign hysterectomy samples described above (𝑛=8 ;
Table 1(a)), as well as complex hyperplasia (𝑛=6involved,
𝑛=6uninvolved);atypicalhyperplasia(𝑛=6involved,𝑛=6
uninvolved; Table 1(b)); and endometrial carcinoma (𝑛=1 2
involved, 𝑛=7 uninvolved myometrium; Table 1(c)). We
wereunabletoobtainuninvolvedmyometrialsamplesfrom5
of the 12 endometrial carcinoma samples because there were
no tissue blocks without carcinoma for these individuals.
2.4. RNA Extraction, Expression Array, and RT-PCR Vali-
dation of Expression Array. RNA extraction was performed
on samples with sufficient tissue. For the FF samples, the
specimens were split for RNA and DNA extraction, and for
FFPE tissues, the weight of the cores for RNA extraction was
recorded (Table 1(a)). Extractions were performed using the
RecoverAll Total Nucleic Acid Isolation Kit (cat no. AM1975,
Applied Biosystems/Ambion, Austin, TX, USA). RNA was
quantitated using the NanoDrop ND-1000 spectrophotome-
ter.QualitywasassessedbymeasuringtheCtthresholdusing
QuantiTect SYBR-Green RT-PCR mix using the protocol
with the WG-DASL kit (Illumina, San Diego, CA, USA) on
a quantitative real-time PCR (qRT-PCR) system (Applied
Biosystems/Life Technologies 7900HT, Carlsbad, CA) in
the Fred Hutchinson Cancer Research Center (FHCRC)
Genomics Core.
The amount of input RNA recommended by Illumina
for the WG-DASL (Illumina, San Diego, CA, USA) is 10–
100ng for RNA derived from FF samples and 50–200ng for
RNA derived from FFPE samples. Therefore, samples were
excluded if they yielded less than 40ng of RNA. Thirteen FF
and 49 FFPE samples were assayed. To test reproducibility
o ft h ea s s a y ,w er a n d o m l ys e l e c t e d8F Fs a m p l e s( 4P i p e l l e ;
4 curettage)and26 FFPE samples (4 benign;3complex, both
involvedanduninvolved;3atypicalinvolvedanduninvolved;
and 5 carcinoma, both involved and uninvolved) to run in
replicate for a total of 21 FF and 75 FFPE samples. The
samples were processed and run on the WG-DASL arrays
by the FHCRC Genomics Shared Resource according to the
manufacturer’s protocol. We examined whether the quality
and quantity of the RNA varied by tissue type and fixation
method, and for the FFPE samples, whether RNA quality
varied by year of sample processing. Various performance
metrics were examined, including the average number of
probes detected (out of the 24,526 transcripts assayed), the
average number of genes detected (out of the 18,391 genes
assayed), the average signal p95, which is the 95th percentile
of the probe intensities on the array, and the signal-to-
n o i s er a t i o ,w h i c hc o m p a r e st h es t r e n g t ho ft h es i g n a lt o
the background signal. Using Genome Studio (Illumina, San
Diego, CA, USA), a detection 𝑃 value was calculated for each
transcript, which represents the probability of observing a
given transcript if in fact the signal is not above the noise,
with the background defined using negative control probes.
Weexaminedtwolevelsofconfidence:𝑃 < 0.01and𝑃 < 0.05.
While a larger number of probes are defined as detected for
𝑃 < 0.05,t h e ym i g h tn o tb ea sr e p r o d u c i b l ea st h ep r o b es e t
defined by 𝑃 < 0.01. Probe concordance is defined as the
percentage of the number of probes with matching detected
calls (at 𝑃 < 0.01 or 𝑃 < 0.05)i nt w or e p l i c a t es a m p l e s ,
over the total number of probes detected in either of the two
samples.
T ov a l i d a t et h er e l a t i v ee x p r e s s i o nv a l u e so b t a i n e db y
WG-DASL, expression levels of six genes were examined
by qRT-PCR in a subset of RNA samples (𝑛=4 4 ). Five
genes (PTEN, CD79B, CD82, S100A4, and FOLR1)w e r e
s e l e c t e db e c a u s et h e yh a v eb e e nr e p o r t e dt ob ea s s o c i a t e d
with endometrial hyperplasia or endometrial carcinoma
(http://www.proteinatlas.org/)[ 6, 19], and one (KCNMA1)
was selected because we observed a wide range of expres-
sion levels (as assayed using WG-DASL) across the tissues
examined. The 44 samples included 13 FF (7 MEM Pipelle
a n d6M E Mc u r e t t a g e )a n d3 1F F P E( 8b e n i g nh y s t e r e c t o m y ,
i n v o l v e dt i s s u ef r o m6c o m p l e xh y p e r p l a s i a s ,5a t y p i c a l
hyperplasias, and 12 endometrial cancers). All 44 samples
wereruninduplicate,resultingin88samplesforatotalof528
data points. Averaged ratios of expression obtained by WG-
DASL and qRT-PCR were compared for the six genes. We
determined the fold difference in expression of a given gene
between two sets oftissues by dividingthelevel ofexpression
in one tissue by the level in the other. We then compared
the fold differences between the tissue types for measures
obtained by DASL versus those obtained by qRT-PCR. The
two different fold changes for a given gene were plotted as
𝑋 and 𝑌 coordinates on a correlation graph and an 𝑅
2 value
wascalculatedtodeterminehowwellthetwosetsofmeasures
were correlated across all 6 genes.
2.5. DNA Extraction and Genotyping. For FF samples, DNA
extractionwasperformedon20Pipelleandcurettagesamples
stored either in MEM (7 Pipelle and 8 curettage samples;
one Pipelle did not have sufficient tissue for extraction) or
RNAlater (5 of 8 curettage samples had sufficient tissue;
no Pipelle samples were stored in RNAlater as the entire
PipellesamplesforresearchwereplacedinMEMtomaximize
quantity). FF samples were minced with scalpel blades and
sheared with NST buffer (146mM NaCl, 10mM Tris Base
(pH 7.5), 1mM CaCl2, 0.5mM MgSO4,0 . 0 5 %B o v i n es e r u m6 Obstetrics and Gynecology International
albumin (BSA), 21mM MgCl2, and 0.2% Igepal) with a 1cc
syringe as needed prior to extraction using Puregene DNA
Isolation Kit (Gentra Systems, Inc., Minneapolis, MN, USA).
DNA was quantitated with PicoGreen (Quant-iT dsDNA
Assay, Invitrogen, Carlsbad CA, USA).
For FFPE samples, we performed DNA extraction on 12
endometrial cancers with paired uninvolved myometrium
(𝑛=7 ; 5 cancers did not have corresponding blocks of uni-
nvolved tissue). The samples were deparaffinized and extra-
cted using the Blood and Tissue DNeasy spin columns
according to the manufacturer’s protocol (Qiagen, Valencia,
CA, USA). DNA quality was assessed by measuring its size
and concentration using a microfluidics-based platform offe-
ring qualitative and semiquantitative analysis (Agilent 2100
Bioanalyzer) with the DNA 7500 LabChip assay (Agilent
Technologies,SantaClara,CA,USA)in theFredHutchinson
Cancer Research Center (FHCRC) Genomics Core.
To evaluate the performance of DNA derived from RNA-
later and FFPE, we planned to genotype the DNA samples
from the 5 FF curettage samples preserved in RNAlater
and the 7 paired FFPE carcinomas and myometrium from
uninvolved tissue blocks on the Genome-Wide Human SNP
Array 6.0 (Affymetrix, Santa Clara, CA, USA) according to
the standard Affymetrix protocol by HudsonAlpha Institute
for Biotechnology, Huntsville, AL, USA. According to that
protocol, DNA was digested with Nsp I and Sty I restriction
enzymes and ligated to adaptors to amplify DNA prior to
g e n o t y p i n g .H o w e v e r ,t h eD N Af r o mF F P Es a m p l e sw a s
fragmented and failed to amplify. Therefore, these samples
were not genotyped. DNA from the RNAlater samples was
resuspended at 50ng/𝜇L prior to analysis on arrays.
3. Results
3.1. RNA Quantity and Quality and WG-DASL Array Perfor-
mance and Reproducibility. We extracted RNA from 15 of 16
FF MEM-preserved biopsy samples (7 Pipelle, 8 curettage)
and 51 of 51 FFPE tissues. The extraction was considered
successful if the sample yielded ≥1.2𝜇g of RNA and had a
260/280 ratio of 1.80 to 2.20. Extraction was successful for
13/15 (87%) FF and 50/51 (98%) FFPE samples. All three
failures were attributed to low yields <1.2𝜇g( 2c u r e t t a g e
samples and one uninvolved FFPE sample from complex
hyperplasia). One postmenopausal individual (patient ID
n o .3 )w a sf o u n dt oh a v ea na t r o p h i ce n d o m e t r i u m .N o t
surprisingly, there was insufficient tissue from both Pipelle
andcurettage(MEMandRNALater)foranalysis(Table 1(a)).
The yields from the FF tissues were higher than those from
the FFPE tissues, but the extracted RNA was very pure for all
of the sample types, as evidenced by the 260/280 ratios being
closeto2.0,whichisthe260/280ratioforpureRNA(Table 2).
A prequalification qRT-PCR assay was performed to test
the quality of the RNA for optimal performance prior to
running the WG-DASL array. A Ct threshold above 29 cycles
w a su s e da sac u t o fft oi n d i c a t ep o o rq u a l i t ys a m p l e s .W h i l e
the FF samples performed slightly better as evidenced by
lower numbers of Ct cycles than did the FFPE samples, all 63
extractedsamplespassedtheprequalificationassay(Table 2).
The overall performance of the RNA samples on the
WG-DASL array was excellent and was only slightly better
for the FF samples than the FFPE samples with respect to
the 95th intensity percentile (p95) and signal-to-noise ratio.
The average number of probes detected (𝑃 < 0.05)w a s
similarforbothFFandFFPEtissues,with75%(18421/24526)
detected for FF, 73% (17959/24526) detected for FFPE, and
69% of genes detected for both groups (12780/18401 for FF
and 12296/18401 for FFPE). The average number of probes
detected at 𝑃 < 0.05 and 𝑃 < 0.01,r e s p e c t i v e l y ,r a n g e df r o m
17,197 (70.1%) and 15,640 (63.8%) for benign hysterectomy
FFPE tissue to 18,640 (76.0%) and 17,064 (69.6%) for FF
Pipelletissue.Theproportionofgenesdetectedwaslowestfor
both benign hysterectomy FFPE tissue and FFPE carcinoma
at 64.8%, and highest for Pipelle, at 70.2% (Table 2). The
Pipelleandcurettagesampleswerehighlycomparablewithan
average expression level correlation 𝑅
2 = 0.939.Th ea v e r a g e
expression level correlations for FF Pipelle and FF curettage
comparedtotheirmatchedFFPEhysterectomysampleswere
similar (0.690 and 0.692, resp.).
To assess the reproducibility of the WG-DASL array, we
assessed the probe correlation for sample replicates. Expre-
ssion levels were highly correlated for both the FF and FFPE
replicate samples (𝑅
2 = 0.991 and 𝑅
2 = 0.985, resp.). Probe
detection concordance rates of the replicates were calculated
at 𝑃 values of <0.05 and <0.01, and all samples had high
concordance with an average of 96% gene overlap at both 𝑃
values(Table 2). Thelowest concordancerateswere observed
in the carcinomas at 94%. There was no difference in the
quality of FFPE RNA samples, probe concordance across
replicates, RNA quality (260/280 ratio), or quantity (RNA
y i e l d ) ,b yy e a ro fs a m p l ec o l l e c t i o n( d a t an o ts h o w n ) .
3.2. Validation of WG-DASL Array with qRT-PCR. Expres-
sion of six genes was assayed using qRT-PCR on the same
RNA samples used for the WG-DASL arrays. Correlations
between fold differences in expression assayed using WG-
DASL and qRT-PCR were evaluated for each gene between
tissue types (FF Pipelle and curettage, FFPE atypical and
complex hyperplasia, FFPE cancer, and uninvolved myome-
trium). Agreement between the two methods was good for
Pipelle and curettage (𝑅
2 =0 . 9 0 ) and cancer and myome-
trium (𝑅
2 = 0.82) but was poor for atypical and complex
hyperplasia samples (𝑅
2 = 0.02). To investigate whether the
atypical or complex hyperplasia RNA samples had deterio-
ratedovertime,weexaminedthefoldchangeinexpressionof
thepanelofgenesasdeterminedbyWG-DASLandqRT-PCR
in the atypical and complex hyperplasia samples compared
to FFPE hysterectomy from the same women. The gene
expression changes between atypical hyperplasia and FFPE
hysterectomy assayed using the WG-DASL and qRT-PCR
were well correlated (𝑅
2 = 0.82), but this was not the case for
complex hyperplasia compared to FFPE hysterectomy (𝑅
2 =
0.18). We did not find evidence of suboptimal qRT-PCR due
to technical issues (e.g., well position in the PCR block),
suggesting the discrepancy was due to sample degradation
s p e c i fi ct ot h ec o m p l e xh y p e r p l a s i as a m p l e si nt h et i m e
between the WG-DASL and qRT-PCR analyses (36 weeks).Obstetrics and Gynecology International 7
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3.3. DNA Quantity, Quality, and Genotyping Success. DNA
extraction was successfully performed on all 20 FF samples
and all 19 FFPE samples (12 carcinomas and 7 uninvolved
myometrium)withexcellentyieldsfromallsampletypes.The
average DNA yield was considerably higher for MEM Pipelle
(46.4𝜇g) than MEM curettage (27.3𝜇g; Table 1(a)), though
the DNA yield from RNAlater curettage was the highest
(54.1𝜇g). The DNA yield from FFPE samples was more
thanadequateforgenomicstudies(40.2𝜇g).Genotypingwas
planned only for the 5 RNAlater-stored curettage samples
and 14 of the FFPE samples (7 carcinomas and their paired
uninvolved myometrium samples). However, because DNA
fragmentation of the FFPE samples was detected, these
samples were not genotyped. Of the five FF RNAlater-stored
curettage samples, one failed due to low input DNA. The
remaining four samples performed well, with call rates of
98.2% to 99.3% (mean, 98.8%).
4. Discussion
This pilot study assessed the feasibility of using fresh and
FFPE uninvolved, hyperplastic, and endometrial carcinoma
specimens collected during routine clinical care for high-
throughput, array-based, and quantitative methodologies.
We demonstrated the ability to extract high-quantity and-
quality RNA from both FF and FFPE specimens for all
tissue types and showed generally successful performance
on the WG-DASL platform. We also demonstrated that
DNA derived from fresh samples stored in RNAlater can be
used successfully for genotyping on the Affymetrix SNP 6.0
platform. The use of RNAlater has implications for simpli-
fying clinical tissue collection, since samples can remain at
room temperature during surgery rather than stored on ice
as is necessary for samples placed in MEM. The SNP 6.0
array platform was not successful for DNA isolated from
FFPE carcinomas and myometrium, despite there being a
substantial volume of DNA. It is possible that our FFPE-
derived DNA sample preparation protocol was not optimal;
others have had success with the SNP 6.0 platform on DNA
derivedfromFFPEtissueafterimplementingadjustedprepa-
rationprotocolstoimprovehybridizationperformanceanda
modified data analysis procedure [20]. The protocol we used
tocollectDNAfromFFPEtissuesyieldedfarmoreDNAthan
is necessary for most genomic applications; future studies
could take a smaller number of cores for DNA extraction
to preserve the tissue for additional assays. The techniques
validated in this pilot study have immediate potential to be
used in samples from our existing longitudinal, retrospective
cohort [4, 8] and to ultimately be translated to future clini-
cal applications with specimens collected during outpatient
gynecologicvisitsforab normalbleedinginwomena triskfor
endometrial neoplasia.
Of particular interest is the assessment of the quality
andquantityofRNA extracted fromPipelle specimens, since
this method of endometrial sampling is minimally invasive
and can be performed repeatedly over time. We demon-
strated that single pass Pipelle tissue specimens (disordered
blinded specimens) are equivalent to curettage specimens
with regard to DNA and RNA yield and RNA performance
on the WG-DASL array. A limitation of our study was a
lack of direct comparison of WG-DASL results between FF
Pipelle and FFPE Pipelle samples. To our knowledge, RNA
and DNA quality and quantity from Pipelle samples have
not been evaluated previously. Because we needed to assure
sufficient endometrium for clinical diagnostic procedures,
and the amount of tissue needed to extract high-quality
RNA and DNA was unknown, we conservatively chose
to use the remaining sample for FF analysis. Given that
the optimal Pipelle endometrial sampling process typically
includes multiple (rather than single) uterine passes, and
that we observed high RNA and DNA yields from the single
pass Pipelle specimens, we propose that tissue collected in
each pass could be split to use for diagnostic histopathologic
evaluation and for research purposes.
We observed moderate success with RNA expression
assayed using the WG-DASL method. While some prior
studies have reported concordance between FF and FFPE
samples [13], others have described poor correlations at the
gene or probe level [15, 16], noting that combinations of
genes (particularly those already identified as members of a
predictivesignature,thatis,forovariancancersubtypesbased
on The Cancer Genome Atlas data) performed reasonably
well. Given that there are no gene expression signatures to
datethatidentifyendometrialhyperplasiasubgroupsthatare
likely to respond to progestin, or are likely to progress, it
is of critical importance to have complete and reliable gene
expressiondata.Thus,whiletheWG-DASLapproachappears
to work reasonably well for validation, it is not as effective
for discovery and is therefore not the ideal platform to use to
identify such subgroups.
Sequencing of both RNA and DNA derived from FFPE
tissues is feasible, but performance of these methods will
need to be assessed within specific endometrial sample types
[21, 22]. Development of novel analytic methods for quality
controlofRNAexpressiondatageneratedfromFFPEtissues,
such as the quality control pipeline described by Waldron
et al. [23], are particularly important as data from multiple
study sites over longer time periods are combined. Addition-
ally, as new methods are developed, such as a novel method
to simultaneously extract DNA, RNA, and microRNA from
a single FFPE sample without splitting it [24], performance
of the methods will need to be evaluated for endometrial
samples.
5. Conclusions
Ou rs t u d yd e m o n s tr a t e sth a tth eP i pe ll es pec i m e n ,wh i c hi sa
common preferred method of clinical endometrial sampling
i nw o m e nw i t ha b n o r m a lb l e e d i n g ,c a nb eu s e de ff e c t i v e l y
for RNA expression studies and also provides a high yield of
DN A.W eproposetha tinthefuture,whilemostofthePipelle
would be reserved for FFPE diagnostic assays, a portion
of the sample could be retained for fresh tissue analysis.
Untilendometrialbiomarkerstudiesbecomearoutineaspect
of care, our study demonstrates that instituting research
practices that collect fresh specimens as well as retaining the
majority of the specimen for FFPE should not affect current
diagnostic capabilitiesand healthoutcomes. RNA expressionObstetrics and Gynecology International 9
data from FF Pipelle samples can be used to generate prog-
nostic signatures, which can then be validated in archived
FFPEtissues.InterrogationoflongitudinalendometrialFFPE
tissuebankstobetterunderstandalterationsthatoccurinthe
progression of endometrial neoplasms is certainly feasible.
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